CSPC Listed in Top 100 Competitive Enterprises in Pharmaceutical Industry

On August 9 to 14, 2023, CPEO (China Health Ecology Organization) was held in Bo'ao. During the event, Sinohealth released an array of lists, such as the 2023 List of Top 100 Competitive Enterprises in Pharmaceutical Industry and the 2023 List of Top 10 Enterprises in R&D. CSPC was included in the two lists.

The 2023 List of Top 100 Competitive Enterprises in Pharmaceutical Industry is a comprehensive list produced by Sinohealth through scientific and quantitative evaluation, with reference to the "2023 Comprehensive Competitiveness Index of China's Pharmaceutical Industry" released by the Medicine and Health Committee of China Enterprise Evaluation Association, industry regulatory databases, Sinohealth's industry database and investigation results. The "2023 Comprehensive Competitiveness Index of China's Pharmaceutical Industry" is obtained with the market value/ estimated value as the primary indicator and the commercialization and R&D capabilities as the secondary indicators. An enterprise's comprehensive competitiveness index is measured by establishing an evaluation model on three dimensions of the enterprise: market value/ estimated value, commercialization capability and R&D capability.

The 2023 List of Top 10 Enterprises in R&D is given by Sinohealth based on the enterprises' R&D inputs and outputs.

CSPC ranked 4th and 5th respectively in the released lists of Top 100 Competitive Enterprises in Pharmaceutical Industry and Top 10 Enterprises in R&D. As a large manufacturer in the pharmaceutical industry in China committed to innovative development, CSPC has long invested a great deal of manpower and material costs in innovative development. Currently, CSPC has established a research team of more than 2000 scientists, with an annual R&D investment of approximately CNY 4 billion, and has built eight R&D platforms, such as nano-formulation, mRNA, and ADC. In addition, CSPC has developed more than 300 pipelines covering many leading and popular targets in the industry. Recently, Citeline, a Norstella company and the world's leading provider of drugs, medical devices, pharmaceutical companies, clinical trials and market intelligence, has released the Pharma R&D Annual Review 2023 and listed the top 25 global pharmaceutical enterprises in pipeline size. CSPC was included for the first time in the list, ranking 23rd.